Veltuzumab - CAS 728917-18-8

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL) .

Immunology/Inflammation related, Integrin

Cytoskeletal Signaling, Immunology/Inflammation

728891

0.979

-20°C

Ice Packs

Inhibitory Antibodies